Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Cresco Labs Inc

Healthcare US CRLBF

0.87USD
-0.044(4.81%)

Last update at 2026-06-03T19:51:00Z

Day Range

0.840.90
LowHigh

52 Week Range

0.432.30
LowHigh

Fundamentals

  • Previous Close 0.91
  • Market Cap341.56M
  • Volume164432
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA125.83M
  • Revenue TTM655.85M
  • Revenue Per Share TTM1.85
  • Gross Profit TTM 324.57M
  • Diluted EPS TTM-0.38

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -95.42200M -10.61600M -146.90200M -126.90500M -256.72700M
Minority interest 4.64M -13.94900M 4.33M 3.80M -22.76300M
Net income -135.40800M -74.43800M -175.52200M -212.04700M -319.59700M
Selling general administrative 247.45M 254.84M 274.63M 350.65M 317.80M
Selling and marketing expenses - - - - -
Gross profit 324.57M 364.45M 362.37M 407.01M 406.35M
Reconciled depreciation 55.74M 65.99M 69.30M 57.73M 44.95M
Ebit - - - 57.27M 111.98M
Ebitda - - - -10.66400M -159.62900M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income 76.94M 109.28M 62.88M 56.93M 87.79M
Other operating expenses - - - - 16.00M
Interest expense 60.03M 57.52M 63.62M 58.52M 52.15M
Tax provision 44.62M 49.87M 32.95M 88.94M 40.11M
Interest income 3.75M 2.92M 2.80M 0.68M 0.94M
Net interest income -56.28000M -54.60100M -60.81900M -57.83700M -51.21100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - 89.10M 40.11M
Total revenue 655.85M 724.34M 770.88M 842.68M 821.68M
Total operating expenses 578.90M 615.06M 708.00M 785.75M 733.89M
Cost of revenue 331.28M 359.89M 408.52M 435.67M 415.33M
Total other income expense net -116.08600M -65.29700M -148.96300M -126.00000M -293.30600M
Discontinued operations - - - - -
Net income from continuing ops -140.04400M -60.48900M -179.85200M -215.84300M -296.83400M
Net income applicable to common shares - - - -215.09600M -319.59700M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1197.30M 1355.36M 1358.47M 1583.69M 1780.46M
Intangible assets 275.34M 293.99M 296.97M 407.59M 437.64M
Earning assets - - - - -
Other current assets 19.91M 2.23M 2.87M 205.44M 16.88M
Total liab 944.80M 967.18M 930.40M 996.01M 982.73M
Total stockholder equity 252.50M 388.18M 428.07M 627.04M 755.55M
Deferred long term liab - - - - -
Other current liab - - - 281.02M 119.95M
Common stock - - - 588.43M 1597.71M
Capital stock 1722.28M 1706.82M 1689.45M 1704.63M 1597.71M
Retained earnings -1500.24400M -1352.48600M -1265.53600M -1076.19800M -841.90700M
Other liab - - - - 110.32M
Good will 208.17M 283.48M 279.70M 330.56M 446.77M
Other assets - - - 139.78M 11.28M
Cash 57.90M 137.56M 103.43M 119.34M 223.54M
Cash and equivalents - - - - -
Total current liabilities 100.18M 94.34M 200.24M 281.02M 288.39M
Current deferred revenue - - - - -
Net debt 366.68M 332.51M 394.28M 349.71M 261.46M
Short term debt - - - - -
Short long term debt 7.48M 9.32M 9.81M - 19.93M
Short long term debt total - - - - -
Other stockholder equity - - - - -0.25400M
Property plant equipment - - - 379.72M 452.89M
Total current assets 259.27M 294.26M 278.09M 326.95M 421.75M
Long term investments - - 0.73M 1.23M 5.91M
Net tangible assets - - - -149.71600M -133.07800M
Short term investments - - - - -
Net receivables 37.89M 51.56M 51.07M 56.49M 44.69M
Long term debt 417.10M 460.75M 497.71M 469.06M 465.08M
Inventory 98.67M 83.34M 107.79M 134.61M 136.64M
Accounts payable 16.54M 13.65M 27.59M 28.09M 32.28M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 14.10M 14.99M 4.42M 9.44M 4.21M
Deferred long term asset charges - - - - -
Non current assets total 938.03M 1061.10M 1080.38M 1257.65M 1358.71M
Capital lease obligations 159.59M 169.57M 175.23M 191.62M 139.73M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -25.22900M -44.58500M -36.57700M -163.93300M
Change to liabilities - - - 0.00000M 21.16M
Total cashflows from investing activities - - - - -163.93300M
Net borrowings -59.73700M -43.78400M 16.69M - 160.75M
Total cash from financing activities -82.08800M -71.47800M -26.90700M -86.64300M 235.00M
Change to operating activities - - - - -22.74100M
Net income -135.40800M -74.43800M -175.52200M -215.09600M -319.59700M
Change in cash -49.91900M 35.73M -12.99000M -104.59200M 85.33M
Begin period cash flow 144.25M 108.52M 121.51M 226.10M 140.77M
End period cash flow 94.33M 144.25M 108.52M 121.51M 226.10M
Total cash from operating activities 72.89M 132.48M 58.56M 18.74M 14.49M
Issuance of capital stock - - - 0.00000M 124.11M
Depreciation 55.74M 65.99M 69.30M 57.73M 44.95M
Other cashflows from investing activities - - - - 33.16M
Dividends paid - - - - -
Change to inventory -18.00500M 18.56M 23.49M -2.66800M -18.42000M
Change to account receivables 12.04M -1.73100M -5.36900M -14.77600M -10.96400M
Sale purchase of stock 0.00000M -0.20000M 0.00000M - -
Other cashflows from financing activities - - - - -69.80300M
Change to netincome - - - - 306.90M
Capital expenditures 38.18M 23.49M 57.88M 86.13M 93.88M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 26.81M 34.97M 15.22M 13.45M -29.06900M
Stock based compensation 11.23M 14.16M 16.36M 23.22M 27.54M
Other non cash items -1.16100M 6.33M 3.86M 9.62M -2.75000M
Free cash flow 34.71M 108.99M 0.68M -67.39100M -82.56600M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CRLBF
Cresco Labs Inc		 -0.044 4.81% 0.87 - 105.26 0.52 1.00 1.31 42.37
ZTS
Zoetis Inc		 1.20 1.57% 77.59 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.58 1.91% 31.01 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 153.91 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.79 1.89% 40.92 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States and Germany. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes, gummies, and pre-rolls under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company offers cannabis flowers under the FloraCal brand; and cannabis oils and variety of bites are available at multiple potency levels under the Mindy's brand, as well as Loud*r brand. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company is headquartered in Chicago, Illinois.

Cresco Labs Inc

600 W. Fulton Street, Chicago, IL, United States, 60661

Key Executives

Name Title Year Born
Mr. Thomas J. Manning Exec. Chairman 1957
Mr. Charles Bachtell Co-Founder, CEO & Director 1979
Mr. Robert M. Sampson Co-Founder & Independent Director 1975
Mr. Dennis M. Olis Chief Financial Officer 1963
Mr. Ty Gent Chief Operating Officer 1959
Ms. Brenna Albert CPA Sr. VP and Controller of Accounting, Treasury & Tax NA
Mr. Zach Marburger Interim Chief Information Officer 1985
Jake Graves Mang. of Investor Relations NA
Mr. John Schetz Gen. Counsel 1977
Ms. Impola Kelli VP of Compliance NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions